Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Sci Rep ; 10(1): 16136, 2020 09 30.
Artigo em Inglês | MEDLINE | ID: mdl-32999313

RESUMO

The complexity of sepsis pathophysiology hinders patient management and therapeutic decisions. In this proof-of-concept study we characterised the underlying host immune response alterations using a standardised immune functional assay (IFA) in order to stratify a sepsis population. In septic shock patients, ex vivo LPS and SEB stimulations modulated, respectively, 5.3% (1/19) and 57.1% (12/21) of the pathways modulated in healthy volunteers (HV), highlighting deeper alterations induced by LPS than by SEB. SEB-based clustering, identified 3 severity-based groups of septic patients significantly different regarding mHLA-DR expression and TNFα level post-LPS, as well as 28-day mortality, and nosocomial infections. Combining the results from two independent cohorts gathering 20 HV and 60 patients, 1 cluster grouped all HV with 12% of patients. The second cluster grouped 42% of patients and contained all non-survivors. The third cluster grouped 46% of patients, including 78% of those with nosocomial infections. The molecular features of these clusters indicated a distinctive contribution of previously described genes defining a "healthy-immune response" and a "sepsis-related host response". The third cluster was characterised by potential immune recovery that underlines the possible added value of SEB-based IFA to capture the sepsis immune response and contribute to personalised management.


Assuntos
Choque Séptico/classificação , Choque Séptico/patologia , Idoso , Biomarcadores/sangue , Infecção Hospitalar , Enterotoxinas/imunologia , Feminino , Expressão Gênica , Perfilação da Expressão Gênica/métodos , Antígenos HLA-DR/metabolismo , Humanos , Lipopolissacarídeos/farmacologia , Lipopolissacarídeos/normas , Masculino , Pessoa de Meia-Idade , Monócitos/metabolismo , Estudo de Prova de Conceito , Sepse/metabolismo , Choque Séptico/mortalidade , Fator de Necrose Tumoral alfa/metabolismo
2.
Anesth Analg ; 130(1): e5-e8, 2020 01.
Artigo em Inglês | MEDLINE | ID: mdl-30399021

RESUMO

Lidocaine has been shown to be clinically beneficial during bariatric surgery. However, information about lidocaine serum concentrations in this setting is scarce. This prospective clinical trial included 42 obese patients undergoing laparoscopic bariatric surgery. They received lidocaine based on adjusted body weight. Administration began with a 1.5 mg·kg bolus of intravenous lidocaine followed by a continuous infusion of 2 mg·kg·hour. After skin closure, administration was decreased to 1 mg·kg·hour until discharge from the recovery room. No serum concentrations of lidocaine were outside the usual accepted range (1.5-5 µg·mL).


Assuntos
Anestésicos Locais/sangue , Gastrectomia , Derivação Gástrica , Laparoscopia , Lidocaína/sangue , Obesidade/cirurgia , Adulto , Anestésicos Locais/administração & dosagem , Anestésicos Locais/efeitos adversos , Índice de Massa Corporal , Esquema de Medicação , Cálculos da Dosagem de Medicamento , Monitoramento de Medicamentos , Feminino , França , Humanos , Infusões Intravenosas , Lidocaína/administração & dosagem , Lidocaína/efeitos adversos , Masculino , Pessoa de Meia-Idade , Obesidade/sangue , Obesidade/diagnóstico , Estudos Prospectivos , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA